ES2558030T3 - Método anticonceptivo oral multifásico de ciclo prolongado - Google Patents

Método anticonceptivo oral multifásico de ciclo prolongado Download PDF

Info

Publication number
ES2558030T3
ES2558030T3 ES07750352.2T ES07750352T ES2558030T3 ES 2558030 T3 ES2558030 T3 ES 2558030T3 ES 07750352 T ES07750352 T ES 07750352T ES 2558030 T3 ES2558030 T3 ES 2558030T3
Authority
ES
Spain
Prior art keywords
equivalent amount
estrogen
phase
ethinyl estradiol
mcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07750352.2T
Other languages
English (en)
Inventor
Herman Ellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Co LLC
Original Assignee
Warner Chilcott Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co LLC filed Critical Warner Chilcott Co LLC
Application granted granted Critical
Publication of ES2558030T3 publication Critical patent/ES2558030T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Abstract

Una combinación multifásica y un kit anticonceptivo que comprende un envase que contiene: (a) de 7 a 14 dosificaciones diarias de una composición de Fase I que contiene un progestógeno en una cantidad equivalente de 0,3 a 1,5 mg de acetato de noretindrona y un estrógeno en una cantidad equivalente de 5 a 15 mcg de etinil estradiol; (b) de 14 a 22 dosificaciones diarias de una composición de Fase II que contiene un progestógeno en una cantidad equivalente de 0,3 a 1,5 mg de acetato de noretindrona y un estrógeno en una cantidad equivalente de 10 a 25 mcg de etinil estradiol; (c) de 20 a 31 dosificaciones diarias de una composición de Fase III que contiene un progestógeno en una cantidad equivalente de 0,3 a 1,5 mg de acetato de noretindrona y un estrógeno en una cantidad equivalente de 15 a 35 mcg de etinil estradiol; y (d) de 2 a 8 dosificaciones diarias de una composición de Fase IV, que contiene i. un estrógeno en una cantidad equivalente de 5 a 20 mcg de etinil estradiol, o ii. un placebo o un componente no esteroideo, o iii. una combinación de i. e ii., donde la cantidad equivalente de etinil estradiol de estrógeno en cada una de las Fases II y III sucesivas es al menos 5 mcg mayor que la cantidad equivalente de etinil estradiol de estrógeno en la fase inmediatamente anterior y donde las dosificaciones combinadas de las composiciones de Fase I, II, III y IV en el kit son de 54 a 58.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES07750352.2T 2006-03-02 2007-02-09 Método anticonceptivo oral multifásico de ciclo prolongado Active ES2558030T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77806706P 2006-03-02 2006-03-02
US778067P 2006-03-02
US79265306P 2006-04-18 2006-04-18
US792653P 2006-04-18
PCT/US2007/003508 WO2007106264A2 (en) 2006-03-02 2007-02-09 Extended cycle multiphasic oral contraceptive method

Publications (1)

Publication Number Publication Date
ES2558030T3 true ES2558030T3 (es) 2016-02-01

Family

ID=38229300

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07750352.2T Active ES2558030T3 (es) 2006-03-02 2007-02-09 Método anticonceptivo oral multifásico de ciclo prolongado

Country Status (8)

Country Link
US (1) US8063030B2 (es)
EP (1) EP1993531B1 (es)
CA (1) CA2640520C (es)
ES (1) ES2558030T3 (es)
IL (1) IL193013A (es)
MX (1) MX2008011074A (es)
SG (1) SG172654A1 (es)
WO (1) WO2007106264A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542854C (en) * 2003-11-14 2012-04-17 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
WO2013090117A1 (en) * 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
CN107810001A (zh) 2015-06-18 2018-03-16 密特拉制药公司 含雌四醇的口腔分散片剂
EP3310333B1 (en) 2015-06-18 2020-04-29 Estetra SPRL Orodispersible dosage unit containing an estetrol component
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35724E (en) * 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
DE4313926A1 (de) * 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
CA2261687A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
WO2002094280A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Means and method for hormonal contraception
PL213122B1 (pl) 2001-12-05 2013-01-31 Duramed Pharmaceuticals Zestaw i preparat zawierajacy estrogen i progestagen
US20040142914A1 (en) 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
CA2478206A1 (en) 2002-03-11 2003-09-25 Patrick Michel Caubel Sulfatase inhibiting continuous progestogen contraceptive regimens
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
EP1624848A4 (en) 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
CN101001631B (zh) 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
KR20060129175A (ko) 2003-10-01 2006-12-15 얀센 파마슈티카 엔.브이. 확장된 3상 피임 요법
CA2542854C (en) 2003-11-14 2012-04-17 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
CA2556459C (en) 2004-03-19 2013-01-15 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
BRPI0510024A (pt) * 2004-05-14 2007-09-25 Irm Llc compostos e composições como modulares de ppar
SG166107A1 (en) 2005-06-29 2010-11-29 Warner Chilcott Co Llc Quadraphasic continuous graduated estrogen contraceptive

Also Published As

Publication number Publication date
US20070207945A1 (en) 2007-09-06
SG172654A1 (en) 2011-07-28
US8063030B2 (en) 2011-11-22
CA2640520A1 (en) 2007-09-20
WO2007106264A2 (en) 2007-09-20
EP1993531B1 (en) 2015-10-14
WO2007106264A3 (en) 2008-05-02
IL193013A0 (en) 2009-08-03
EP1993531A2 (en) 2008-11-26
IL193013A (en) 2011-11-30
CA2640520C (en) 2014-04-22
MX2008011074A (es) 2008-09-10

Similar Documents

Publication Publication Date Title
ES2558030T3 (es) Método anticonceptivo oral multifásico de ciclo prolongado
ES2399105T3 (es) Anticonceptivo estrogénico cuadrifásico graduado de manera continua
JP2007535519A5 (es)
RU2007148080A (ru) Составы и способы для лечения симптомов, связанных с циклом
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
MEP36008A (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
NO179311B (no) Flerfasekombinasjons- og kontraseptiv pakke
RU2009120528A (ru) Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла
HUP0301042A2 (hu) Fogamzásgátlásra használható gyógyszerkészítmény
CA2542854A1 (en) Graduated estrogen contraceptive
MX2007013137A (es) Regimen anticonceptivo con dosificacion de estrogeno ampliada.
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
JP2005516913A5 (es)
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
NO20072893L (no) Fast, peroralt prevensjonsmiddel
NO20072687L (no) Farmasoytisk prevensjonspreparat
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
RU2006114791A (ru) Продленные режимы трехфазных контрацептивов
JP2003522795A5 (es)
KR960700726A (ko) 수정의 방지 또는 억제방법(method of preventing of inhibting fertilization)
SI1937274T1 (sl) Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
RU2009140372A (ru) Новый режим с дроспиреноном/17b-эстрадиолом, фармацевтический комбинированный продукт и набор для выполнения этого режима